Health-Related Quality of Life and Cognitive Performance During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures: A Prospective, Observational Study in Europe
In patients with predominantly difficult-to-treat FOS, BRV add-on was associated with good HRQoL and cognitive functioning. Cognitive functioning remained stable for 12 months after BRV initiation in most patients; nearly one-quarter experienced significant improvements. At 12 months, 46.6% of patients reported clinically meaningful HRQoL improvements, and most showed an improved overall condition.
Authors
- Anne‐Liv Schulz
- Eduardo Rubio-Nazábal (ORCID: https://orcid.org/0000-0003-3049-987X)
- F Brock
- Bernhard J. Steinhoff (ORCID: https://orcid.org/0000-0001-5995-5862)
- Iryna Leunikava
- Dimitrios Bourikas (ORCID: https://orcid.org/0009-0005-4503-0734)
- Marian Majoie (ORCID: https://orcid.org/0000-0003-0579-8122)
Institutions
- Universidade da Coruña (ES)
- University of Freiburg (DE)
- Maastricht University (NL)
- Kempenhaeghe (NL)
- Diakonie Kork (DE)
- UCB Pharma (Germany) (DE)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1007/s40120-024-00698-3
- Citations
- 4
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.88
Funders
- B. Braun Melsungen
- Zogenix
- GW Pharmaceuticals
- SK Life Science
- Eisai
- Angelini Pharma
- Neuraxpharm
- Arvelle Therapeutics
- UCB Pharma